PT948965E - Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano - Google Patents

Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano

Info

Publication number
PT948965E
PT948965E PT98931040T PT98931040T PT948965E PT 948965 E PT948965 E PT 948965E PT 98931040 T PT98931040 T PT 98931040T PT 98931040 T PT98931040 T PT 98931040T PT 948965 E PT948965 E PT 948965E
Authority
PT
Portugal
Prior art keywords
stabilizable
medicinal compositions
compositions containing
epoxymorphinan derivative
epoxymorphinan
Prior art date
Application number
PT98931040T
Other languages
English (en)
Portuguese (pt)
Inventor
Michio Hara
Yasuhide Horiuchi
Nobuyuki Hanamura
Ryoji Yoshii
Takao Aoki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PT948965E publication Critical patent/PT948965E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT98931040T 1997-07-11 1998-07-10 Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano PT948965E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18695097 1997-07-11

Publications (1)

Publication Number Publication Date
PT948965E true PT948965E (pt) 2004-08-31

Family

ID=16197570

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98931040T PT948965E (pt) 1997-07-11 1998-07-10 Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano

Country Status (15)

Country Link
US (1) US6372755B2 (enExample)
EP (1) EP0948965B1 (enExample)
JP (3) JP3617055B2 (enExample)
KR (1) KR100514963B1 (enExample)
CN (1) CN100379419C (enExample)
AT (1) ATE268178T1 (enExample)
AU (1) AU740404B2 (enExample)
CA (1) CA2265767C (enExample)
DE (1) DE69824277T2 (enExample)
DK (1) DK0948965T3 (enExample)
ES (1) ES2217563T3 (enExample)
NO (1) NO318831B1 (enExample)
PT (1) PT948965E (enExample)
TW (1) TWI285644B (enExample)
WO (1) WO1999002158A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
TWI282275B (en) * 2000-08-17 2007-06-11 Control Ox Oy Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
JP4880813B2 (ja) * 2000-10-26 2012-02-22 第一三共株式会社 外用消炎鎮痛剤組成物
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
JP4963670B2 (ja) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ, エルエルシー 栄養補助サプリメントおよびそれを処理する方法
AU2005244059A1 (en) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
EP1845787B1 (en) * 2005-01-27 2015-04-15 Erimos Pharmaceuticals LLC Formulations for injection of catecholic butanes, including ndga compounds, into animals
CN101150955B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 递送包括ndga化合物的儿茶酚丁烷的口服制剂
TWI286941B (en) * 2005-07-27 2007-09-21 Anagen Therapeutics Inc Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
CA2685131C (en) * 2007-04-26 2015-05-19 Toray Industries, Inc. Stable solid preparation containing 4,5-epoxymorphinan derivative
WO2008143240A1 (ja) * 2007-05-21 2008-11-27 Toray Industries, Inc. 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
DK2356989T3 (en) * 2008-10-24 2018-05-07 Toray Industries Stable tablet containing 4,5-epoxymorphinane derivative
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
WO2010139752A2 (en) * 2009-06-04 2010-12-09 Alk Ag Stabilised composition comprising at least one adrenergic compound
HUE045889T2 (hu) 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
JP5750278B2 (ja) * 2011-02-28 2015-07-15 東洋カプセル株式会社 カンデサルタンシレキセチルのカプセル充填用組成物
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
JP6247118B2 (ja) * 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
US10561628B2 (en) * 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
BR112017019920B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
JP5918895B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN109562109A (zh) * 2016-07-29 2019-04-02 东丽株式会社 光稳定性提高的固体制剂
JP6131379B1 (ja) * 2016-12-28 2017-05-17 森下仁丹株式会社 4,5−エポキシモルヒナン誘導体含有製剤
EP3603643B1 (en) * 2017-03-31 2021-09-15 Toray Industries, Inc. Tableted medicinal composition comprising nalfurafine
CA3091752A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
JP7312751B2 (ja) 2018-07-30 2023-07-21 第一三共株式会社 安定化剤を含有する医薬品の固形製剤
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
WO2020205735A1 (en) 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
WO2021100728A1 (ja) * 2019-11-20 2021-05-27 塩野義製薬株式会社 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤
MX2023014819A (es) 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765694B2 (ja) * 1988-01-29 1998-06-18 日清バーディシェ株式会社 酸化感受性化合物の安定な組成物
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
JP2525552B2 (ja) * 1992-01-23 1996-08-21 東レ株式会社 モルヒナン誘導体および医薬用途
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid

Also Published As

Publication number Publication date
TWI285644B (en) 2007-08-21
US6372755B2 (en) 2002-04-16
DE69824277T2 (de) 2004-09-23
DE69824277D1 (de) 2004-07-08
NO991152L (no) 1999-05-10
KR20000068528A (ko) 2000-11-25
KR100514963B1 (ko) 2005-09-15
AU740404B2 (en) 2001-11-01
ATE268178T1 (de) 2004-06-15
EP0948965A4 (en) 2002-10-16
ES2217563T3 (es) 2004-11-01
US20010004637A1 (en) 2001-06-21
CN100379419C (zh) 2008-04-09
EP0948965A1 (en) 1999-10-13
WO1999002158A1 (fr) 1999-01-21
DK0948965T3 (da) 2004-07-05
NO991152D0 (no) 1999-03-10
CA2265767A1 (en) 1999-01-21
JP2005002123A (ja) 2005-01-06
JP3617055B2 (ja) 2005-02-02
CN1237106A (zh) 1999-12-01
EP0948965B1 (en) 2004-06-02
JP3743449B2 (ja) 2006-02-08
AU8128298A (en) 1999-02-08
JP4311369B2 (ja) 2009-08-12
NO318831B1 (no) 2005-05-09
CA2265767C (en) 2007-12-04
JP2005247866A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
EP0948965A4 (en) STABLE MEDICAL COMPOSITIONS CONTAINING 4,5-EPOXYMORPHINE DERIVATIVES
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
CY1105112T1 (el) Διαμορφωσεις δια καταπολεμησιν ανθρωπινων φθειρων, πepιεχουσαι σπινοσυνη (spinosyn)
AU7102201A (en) Propane-1,3-dione derivatives
DZ2686A1 (fr) Formulation pharmaceutique orale à libération pulsée.
DZ2569A1 (fr) Dérivés 1,2,3,4-tétrahydronaphtalène substitués.
DE69833464D1 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
PT955042E (pt) Composicao farmaceutica a base de estrogenio e de progesterona
DK0588539T3 (da) Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
AU2001244614A1 (en) Oily compositions containing highly fat-soluble drugs
IL133397A (en) Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin
ATE212635T1 (de) 1,3,8-triazaspiro(4,5)decan-4-on-derivate
IS5730A (is) Setin tíazóló-pýridazín afleiða, lyfjasamsetningar gerðar úr henni
PL346166A1 (en) Pesticidal compositions comprising 1,2,3-benzothiadiazole derivatives
IS4774A (is) Lyfjafræðilegar samsetningar með D-vítamín hliðstæðum
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
AU5016990A (en) Stabilized fat-soluble vitamin compositions
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
TR199501082A2 (tr) Farmasötik formülasyonlar.
AU6724500A (en) Motorcyclist suit
ZA200006557B (en) Agents for combating plant pests.
EP0419890A3 (en) Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
BG104692A (en) Extended release tiagabine formulation